Revive Therapeutics Secures $246,920 in First Tranche of Non-Brokered Private Placement

Details of Revive Therapeutics’ Private Placement and Unit Structure

The first tranche closing marks the initial phase of Revive Therapeutics’ non-brokered private placement. The company issued 7,716,250 units at $0.032 each, generating $246,920 in gross proceeds before deductions. This structure allows investors immediate equity participation combined with warrants, a common approach in life sciences financing to balance current capital needs with future dilution considerations.

Each unit consists of one common share and one common share purchase warrant. Warrants allow holders to buy one additional common share at $0.05 per share, exercisable for 36 months from closing. The warrant exercise price represents a 56% premium to the unit price, potentially incentivizing warrant exercise if the share price appreciates significantly during the term.

Allocation of Proceeds and Capital Use Strategy

Revive Therapeutics plans to allocate the gross proceeds primarily toward working capital needs. The company did not specify detailed allocation percentages or operational priorities. Typically, working capital covers operational expenses, administrative costs, and near-term development activities. As a life sciences firm focused on infectious diseases and medical countermeasures, Revive’s working capital supports ongoing preclinical research, clinical trials, regulatory engagement, and operational infrastructure.

Current development efforts include exploring bucillamine for infectious diseases, nerve agent exposure, and long COVID, among other indications. These activities require sustained funding, which the raised capital will help support.

Finders’ Fees and Broker Warrants Issued

In connection with the tranche closing, Revive Therapeutics paid finders' fees totaling $17,433.60 and issued 537,300 broker warrants as additional compensation. Broker warrants carry the same terms as investor warrants: exercisable at $0.05 per share for 36 months from closing.

Issuing broker warrants aligns finders’ interests with shareholder outcomes and helps preserve capital by compensating intermediaries partly through equity-linked instruments rather than cash alone. The total value to finders depends on the underlying share price performance during the warrant term.

Hold Period and Regulatory Restrictions

All securities issued in the first tranche are subject to a four-month-and-one-day hold period from issuance, per Canadian securities regulations. For investors in the July 15, 2026 closing, this hold period expires on November 16, 2026, barring extensions.

This hold period prevents immediate resale, stabilizes the shareholder base post-financing, and demonstrates commitment from participants. During this period, holders retain full voting rights and economic participation, including potential dividends.

Company Focus on Infectious Diseases and Medical Countermeasures

Revive Therapeutics is a life sciences company strategically focused on infectious diseases and medical countermeasures. Its R&D prioritizes therapeutic candidates addressing unmet medical needs while leveraging regulatory incentives such as accelerated or breakthrough therapy designations.

The pipeline includes bucillamine, investigated for multiple indications including infectious diseases, nerve agent exposure, and long COVID. This multi-indication strategy maximizes the potential return on investment and provides flexibility based on clinical and regulatory developments.

Multi-Market Listings and Investor Access

Revive Therapeutics trades on the Canadian Securities Exchange (CSE: RVV), OTCQB in the U.S. (RVVTF), and Frankfurt Exchange (31R). This multi-jurisdictional presence broadens investor access across Canada, the U.S., and Europe, enhancing liquidity and share price discovery.

Multiple listings support the company’s international regulatory strategies and accommodate diverse investor preferences regarding market access and oversight.

Future Tranches and Capital Raising Plans

The company indicated it will provide updates on further closings under the private placement, confirming the first tranche is an initial phase. Multi-tranche placements are common in biotech, allowing phased capital raises to align with milestones and market conditions.

Future tranche pricing and timing remain at the company’s discretion and may differ based on financial condition, development progress, or market sentiment.

Regulatory Compliance and CSE Review

The announcement includes standard disclaimers noting the Canadian Securities Exchange and its Regulation Services Provider have not reviewed or accepted responsibility for the release’s adequacy or accuracy. This reflects typical CSE policy focusing on disclosure standards rather than endorsement.

The private placement complied with applicable Canadian securities exemptions, relying on accredited investor or minimum purchase exemptions, with all participants meeting eligibility criteria.

Forward-Looking Statements and Risks

The company’s disclosure contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed in the management’s discussion and analysis for the three and nine months ended March 31, 2026, filed May 29, 2026, available on www.sedarplus.ca.

Key risks include clinical outcomes, regulatory approvals, competition, intellectual property, and capital adequacy. Revive is not obligated to update forward-looking information unless required by law.

Financing Context and Market Environment

The successful first tranche closing demonstrates investor willingness to participate at the stated pricing and terms. While $246,920 is modest, it reflects the company’s development stage and current market conditions for life sciences equities.

Life sciences financing is cyclical and influenced by market sentiment, clinical data, and regulatory events. Revive’s ability to complete future tranches depends on maintaining investor confidence and achieving development milestones. The immediate share price impact was not publicly available at announcement time.